Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPH1 | P17752 | 5/20 | 0.57 |
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31369706 | 0.84 | HSD17B10 (0.51) | TPH1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL30722995 | 0.82 | TPH1 (0.60) | TPH1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL25356472 | 0.82 | TPH1 (0.60) | TPH1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL25356476 | 0.82 | TPH1 (0.60) | TPH1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL31303988 | 0.82 | TPH1 (0.60) | TPH1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL25357127 | 0.82 | TPH1 (0.60) | TPH1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL31295364 | 0.80 | SLC7A5 (0.54) | TPH1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL29462215 | 0.80 | SLC7A5 (0.54) | TPH1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL12273163 | 0.80 | SLC7A5 (0.54) | TPH1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL30673627 | 0.80 | SLC7A5 (0.54) | TPH1SLC7A5PTGS1ALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9605024-B2 | PAR4 agonist peptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-28 | — | — | US | disclosed |
| US-9605024-B2 | PAR4 agonist peptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160304560-A1 | PAR4 AGONIST PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-20 | — | — | US | disclosed |
| US-20160304560-A1 | PAR4 AGONIST PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-20 | — | — | US | disclosed |
| US-20160274108-A1 | DIAGNOSTIC METHODS FOR PAR4 ANTAGONIST THERAPY | BRISTOL-MYERS SQUIBB COMPANY | 2016-09-22 | — | — | US | disclosed |
| US-20160274108-A1 | DIAGNOSTIC METHODS FOR PAR4 ANTAGONIST THERAPY | BRISTOL-MYERS SQUIBB COMPANY | 2016-09-22 | — | — | US | disclosed |
| US-9303065-B2 | PAR4 agonist peptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-05 | — | — | US | disclosed |
| US-9303065-B2 | PAR4 agonist peptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150158910-A1 | PAR4 AGONIST PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY | 2015-06-11 | — | — | US | disclosed |
| US-20150158910-A1 | PAR4 AGONIST PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY | 2015-06-11 | — | — | US | disclosed |
| WO-2015061733-A1 | DIAGNOSTIC METHODS FOR PAR4 ANTAGONIST THERAPY | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2015-04-30 | — | — | WO | disclosed |
| US-8927688-B2 | PAR4 agonist peptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927688-B2 | PAR4 agonist peptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-06 | — | — | US | disclosed |
| US-8835020-B2 | Blue fluorescent composition and organic electroluminescent device using the same | LG DISPLAY CO., LTD. (KR) | 2014-09-16 | — | — | US | disclosed |
| US-20130289238-A1 | PAR4 AGONIST PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY | 2013-10-31 | — | — | US | disclosed |
| WO-2013163248-A1 | PAR4 AGONIST PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-31 | — | — | WO | disclosed |
| US-20130289238-A1 | PAR4 AGONIST PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY | 2013-10-31 | — | — | US | disclosed |
| US-20070231858-A1 | ENZYMATIC PREPARATION OF (S) AMINO ACID FROM (R,S) AMINO ACID OR FROM KETO ACID | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070231858-A1 | ENZYMATIC PREPARATION OF (S) AMINO ACID FROM (R,S) AMINO ACID OR FROM KETO ACID | SRR, ASNS, BCAT2 | TPH1 765/4885SLC7A5 89/4885PTGS1 3141/4885 |
| US-20130289238-A1 | PAR4 AGONIST PEPTIDES | F2RL3, F2R, F2RL1 | TPH1 1177/4885SLC7A5 2642/4885PTGS1 1252/4885 |
| US-20150158910-A1 | PAR4 AGONIST PEPTIDES | F2RL3, F2R, F2RL1 | TPH1 1177/4885SLC7A5 2642/4885PTGS1 1252/4885 |
| US-20160274108-A1 | DIAGNOSTIC METHODS FOR PAR4 ANTAGONIST THERAPY | F2RL3, F2RL1, F2R | TPH1 757/4885SLC7A5 4642/4885PTGS1 459/4885 |
| US-20160304560-A1 | PAR4 AGONIST PEPTIDES | F2RL3, F2R, F2RL1 | TPH1 1177/4885SLC7A5 2642/4885PTGS1 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.